WallStSmart

Booking Holdings Inc (BKNG)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 129% more annual revenue ($63.32B vs $27.69B). BKNG leads profitability with a 22.2% profit margin vs 11.8%. BKNG appears more attractively valued with a PEG of 0.73. BKNG earns a higher WallStSmart Score of 76/100 (B+).

BKNG

Strong Buy

76

out of 100

Grade: B+

Growth: 8.7Profit: 9.5Value: 6.7Quality: 7.5
Piotroski: 4/9Altman Z: 4.05

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 5.3Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BKNGUndervalued (+8.9%)

Margin of Safety

+8.9%

Fair Value

$188.04

Current Price

$165.93

$22.11 discount

UndervaluedFair: $188.04Overvalued
PFEUndervalued (+29.4%)

Margin of Safety

+29.4%

Fair Value

$37.48

Current Price

$25.68

$11.80 discount

UndervaluedFair: $37.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BKNG6 strengths · Avg: 9.7/10
Return on EquityProfitability
225.7%10/10

Every $100 of equity generates 226 in profit

EPS GrowthGrowth
240.0%10/10

Earnings expanding 240.0% YoY

Debt/EquityHealth
-3.4610/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.0510/10

Safe zone — low bankruptcy risk

Market CapQuality
$132.72B9/10

Large-cap with strong market position

Profit MarginProfitability
22.2%9/10

Keeps 22 of every $100 in revenue as profit

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

BKNG0 concerns · Avg: 0/10

No major concerns identified

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : BKNG

The strongest argument for BKNG centers on Return on Equity, EPS Growth, Debt/Equity. Profitability is solid with margins at 22.2% and operating margin at 25.0%. Revenue growth of 16.2% demonstrates continued momentum.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : BKNG

No major red flags identified for BKNG, but monitor valuation.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

BKNG profiles as a growth stock while PFE is a value play — different risk/reward profiles.

BKNG carries more volatility with a beta of 1.10 — expect wider price swings.

BKNG is growing revenue faster at 16.2% — sustainability is the question.

BKNG generates stronger free cash flow (3.1B), providing more financial flexibility.

Bottom Line

BKNG scores higher overall (76/100 vs 55/100), backed by strong 22.2% margins and 16.2% revenue growth. PFE offers better value entry with a 29.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Booking Holdings Inc

CONSUMER CYCLICAL · TRAVEL SERVICES · USA

Booking Holdings Inc. is an American travel technology company organized in Delaware and based in Norwalk, Connecticut, that owns and operates several travel fare aggregators and travel fare metasearch engines including namesake and flagship Booking.com, Priceline.com, Agoda.com, Kayak.com, Cheapflights, Rentalcars.com, Momondo, and OpenTable.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?